Management of Compensatory Hyperaldosteronism in Hepatorenal Syndrome

Pathophysiological Basis

Compensatory hyperaldosteronism in hepatorenal syndrome occurs due to activation of the renin-angiotensin-aldosterone system, which is a response to splanchnic vasodilation, reduced effective arterial blood volume, and decreased mean arterial pressure 1, 4
This activation causes renal vasoconstriction and shifts the renal autoregulatory curve, making renal blood flow more sensitive to changes in mean arterial pressure 1
The pathophysiology involves four key factors: splanchnic vasodilation, sympathetic nervous system activation, impaired cardiac function, and increased synthesis of vasoactive mediators 1

The European Association for the Study of the Liver recommends terlipressin (1 mg IV every 4-6 hours) combined with albumin as the first-line pharmacological treatment for HRS type 1 4, 3
Initial albumin dosing should be 1 g/kg on day 1 followed by 40 g/day to improve circulatory function 2
If serum creatinine does not decrease by at least 25% after 3 days, increase terlipressin dose stepwise to a maximum of 2 mg every 4 hours 4, 3
Continue treatment until serum creatinine decreases below 1.5 mg/dL (133 μmol/L) 2
Response to therapy is characterized by progressive reduction in serum creatinine, increased arterial pressure, increased urine volume, and increased serum sodium concentration 2

In regions where terlipressin is unavailable, midodrine plus octreotide plus albumin can be used 3
- Midodrine: Start at 7.5 mg orally three times daily, titrate up to 12.5-15 mg three times daily 2, 3
- Octreotide: 100-200 μg subcutaneously three times daily 2, 3
- Albumin: 10-20 g IV daily for up to 20 days 3
Norepinephrine (0.5-3 mg/h) with albumin is another alternative, requiring ICU monitoring 2, 5

Monitor urine output, fluid balance, arterial pressure, and vital signs carefully 1
Central venous pressure monitoring is ideal to help manage fluid balance 1
Median time to response is approximately 14 days, with shorter response times in patients with lower baseline serum creatinine 2
Predictors of good response include serum bilirubin <10 mg/dL before treatment and an increase in mean arterial pressure >5 mmHg at day 3 of treatment 2, 5

TIPS may improve renal function in selected patients with HRS who have responded partially to medical therapy 4
However, TIPS has limited applicability as many patients have contraindications to its use 4

Consider renal replacement therapy in patients who do not respond to vasoconstrictor therapy and fulfill criteria for renal support 4
Continuous renal replacement therapy is preferable to intermittent hemodialysis in hemodynamically unstable patients 5
However, RRT is not recommended as stand-alone therapy unless patients are candidates for liver transplantation 5

Liver transplantation is the definitive treatment for both type 1 and type 2 HRS, with survival rates of approximately 65% in type 1 HRS 4, 3
Patients with type 1 HRS should be given priority for transplantation due to high mortality while on the waiting list 4
Treatment of HRS before transplantation may improve outcomes after transplantation 4

Norfloxacin (400 mg/day) can reduce the incidence of HRS in advanced cirrhosis 2, 3
Pentoxifylline (400 mg three times daily) may prevent HRS development in patients with severe alcoholic hepatitis 2, 3
Albumin infusion together with antibiotics for spontaneous bacterial peritonitis reduces the risk of developing HRS and improves survival 1

Avoid the triple combination of ACE inhibitors, ARBs, and aldosterone antagonists due to risk of hyperkalemia 6
Monitor for ischemic complications with terlipressin (arrhythmia, angina, splanchnic and digital ischemia) 7